STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost radiation for head and neck cancer
Disease control Recruiting nowThis early-phase trial is testing whether adding the experimental drug ipatasertib to standard chemotherapy and radiation can better control advanced head and neck cancer. About 46 adults with certain types of head and neck cancer will receive the combination to find the safest d…
Matched conditions: STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:49 UTC
-
Could a chemo drug boost radiation for head and neck cancer survivors?
Disease control Recruiting nowThis study compares radiation therapy alone versus radiation plus the chemotherapy drug cisplatin in people with stage III-IVA head and neck cancer who have already had surgery to remove their tumor. About 189 participants will be randomly assigned to one of the two treatments. T…
Matched conditions: STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 17, 2026 05:49 UTC
-
New combo therapy aims to boost survival in returning head and neck cancer
Disease control Recruiting nowThis study tests whether adding chemotherapy or a chemo-immunotherapy combination before standard salvage surgery helps people with a specific type of head and neck cancer that has come back or persisted. About 180 adults with PD-L1 positive cancer will be randomly assigned to on…
Matched conditions: STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside their usual treatment. The goal is to improve quality of life…
Matched conditions: STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 17, 2026 05:50 UTC
-
New imaging study reveals hidden vascular damage from radiation in head and neck cancer
Knowledge-focused Recruiting nowThis study uses special PET/CT scans to see how radiation therapy affects blood vessels in the neck of people with head and neck cancers. About 20 adults will get two types of PET scans before and after radiation. The goal is to compare the scans and learn more about radiation's …
Matched conditions: STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer do or don't follow swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the illness affect exercise habits. The goal is to learn what h…
Matched conditions: STAGE IVA OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC